| | | | | | | | | | |
|
|
| Dockets Entered
On February 7, 2006
Table of Contents
|
|
|
|
|
|
|
| Docket #
|
| Title
|
|
|
|
|
| 2004D-0555
|
| Class II Special Controls Draft Guidance; Labeling for Male Condoms Made of Natural Rubber Latex
|
|
|
| 2004P-0074
|
| oxandrolone and widely used anti-coagulant durgs containing the active drug warfarin
|
|
|
| 2005N-0157
|
| Agency Information Collection Activities: Proposed Collection; Postmarketing Adverse Drug Experience Reporting
|
|
|
| 2005N-0285
|
| Current Good Manufacturing Practice Regulation and Investigational New Drugs
|
|
|
| 2005N-0345
|
| Drug Approvals: Circumstances under which an active ingredient may be simultaneously marketed in both a prescription drug product and an over-the-counter drug product
|
|
|
| 2005N-0374
|
| Use of Ozone-Depleting Substance: Essential-Use Determination of Over the Counter Epinephrine Metered-Dose Inhalers
|
|
|
| 2005P-0096
|
| ANDA 77-421 Loratadine Syrup- Hives relief
|
|
|
| 2005P-0323
|
| Immediately remove Adderall and Adderall XR from the market for safety reasons
|
|
|
| 2005P-0383
|
| refuse to approve any ANDA for generic oral products containing oxandrolone until the expiration od that exclusitity peroid on June 20, 2008.
|
|
|
| 2005P-0411
|
| Seeking FDA Actions to Counter Flagrant Violations of the Law by Pharmacies Compounding Bio-Identical Hormone Replacement Therapy Drugs
|
|
|
| 2005P-0459
|
| To enforce ban on carbon monoxide gas in fresh meat packaging
|
|
|
| 2006N-0045
|
| Behavior-Based Blood Donor Deferrals in the Era of Nucleic Acid Testing (NAT); Public Workshop; Request for Comments
|
|
|
| 2004D-0555
|
| Class II Special Controls Draft Guidance; Labeling for Male Condoms Made of Natural Rubber Latex
|
|
|
| C
6
|
| Catholics for a Free Choice (CFFC)
|
| Vol #:
|
| 1
|
|
|
| 2004P-0074
|
| oxandrolone and widely used anti-coagulant durgs containing the active drug warfarin
|
|
|
| SUP
4
Attachment
|
| Savient Pharmaceuticals, Inc. (Savient)
|
| Vol #:
|
| 1
|
|
|
| 2005N-0157
|
| Agency Information Collection Activities: Proposed Collection; Postmarketing Adverse Drug Experience Reporting
|
|
|
| N
2
|
| FDA
|
| Vol #:
|
| 1
|
|
|
| 2005N-0285
|
| Current Good Manufacturing Practice Regulation and Investigational New Drugs
|
|
|
| C
1
|
| University of Texas MD Anderson Cancer Center
|
| Vol #:
|
| 1
|
|
|
| 2005N-0345
|
| Drug Approvals: Circumstances under which an active ingredient may be simultaneously marketed in both a prescription drug product and an over-the-counter drug product
|
|
|
| C 498
|
| J. Flippen
|
| Vol #:
|
| 165
|
|
|
| 2005N-0374
|
| Use of Ozone-Depleting Substance: Essential-Use Determination of Over the Counter Epinephrine Metered-Dose Inhalers
|
|
|
| C 5
|
| S. Mawhinney
|
| Vol #:
|
| 1
|
|
|
| C 6
|
| M. Supler
|
| Vol #:
|
| 1
|
|
|
| 2005P-0096
|
| ANDA 77-421 Loratadine Syrup- Hives relief
|
|
|
| LET
2
|
| HFD-007 to Silarx Pharmaceuticals, Inc
|
| Vol #:
|
| 2
|
|
|
| 2005P-0323
|
| Immediately remove Adderall and Adderall XR from the market for safety reasons
|
|
|
| LET
1
|
| HFD-005 to David S. Lowe
|
| Vol #:
|
| 1
|
|
|
| 2005P-0383
|
| refuse to approve any ANDA for generic oral products containing oxandrolone until the expiration od that exclusitity peroid on June 20, 2008.
|
|